What men want: Results from a national survey on decision making for prostate cancer treatment and research participation

Abstract Data comparing outcomes in prostate cancer and factors affecting treatment choice are sparse. To inform the design of a comparative effectiveness clinical trial, we engaged patients in developing a 28‐question survey about decision making on treatment and research participation and disperse...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nancy P. Mendenhall, Sarah M. Rausch Osian, Curtis M. Bryant, Bradford S. Hoppe, Christopher G. Morris
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	Therapeutics. Pharmacology RM1-950 Public aspects of medicine RA1-1270
Acceso en línea:	https://doaj.org/article/e601dda73bf44c2c8efdfb3f7a3a001a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e601dda73bf44c2c8efdfb3f7a3a001a
record_format	dspace
spelling	oai:doaj.org-article:e601dda73bf44c2c8efdfb3f7a3a001a2021-11-19T17:51:35ZWhat men want: Results from a national survey on decision making for prostate cancer treatment and research participation1752-80621752-805410.1111/cts.13090https://doaj.org/article/e601dda73bf44c2c8efdfb3f7a3a001a2021-11-01T00:00:00Zhttps://doi.org/10.1111/cts.13090https://doaj.org/toc/1752-8054https://doaj.org/toc/1752-8062Abstract Data comparing outcomes in prostate cancer and factors affecting treatment choice are sparse. To inform the design of a comparative effectiveness clinical trial, we engaged patients in developing a 28‐question survey about decision making on treatment and research participation and dispersed it among men greater than or equal to 50 years of age. The 1046 respondents ranked long‐term clinical outcomes as most important in making treatment decisions, specific functional outcomes as slightly less important, and duration, location, and cost of treatment as least important. Treatment choice was strongly impacted by side effect profile. Responses to whether the subject would agree to participation in a randomized trial between two types of radiation with minimal differences in outcomes were “yes” in 15%, “no” in 39%, and “undecided” in 46%. Responses to whether the subject would agree to participation in a randomized trial between two treatment durations with similar outcomes were yes in 36%, no in 24%, and undecided in 40%. Findings suggest many potential patients have strong treatment preferences and are averse to randomization, particularly when outcomes of importance may be affected. Patient engagement in study design and novel nonrandomized trial designs may offer a path to increase clinical trial success.Nancy P. MendenhallSarah M. Rausch OsianCurtis M. BryantBradford S. HoppeChristopher G. MorrisWileyarticleTherapeutics. PharmacologyRM1-950Public aspects of medicineRA1-1270ENClinical and Translational Science, Vol 14, Iss 6, Pp 2314-2326 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950 Public aspects of medicine RA1-1270
spellingShingle	Therapeutics. Pharmacology RM1-950 Public aspects of medicine RA1-1270 Nancy P. Mendenhall Sarah M. Rausch Osian Curtis M. Bryant Bradford S. Hoppe Christopher G. Morris What men want: Results from a national survey on decision making for prostate cancer treatment and research participation
description	Abstract Data comparing outcomes in prostate cancer and factors affecting treatment choice are sparse. To inform the design of a comparative effectiveness clinical trial, we engaged patients in developing a 28‐question survey about decision making on treatment and research participation and dispersed it among men greater than or equal to 50 years of age. The 1046 respondents ranked long‐term clinical outcomes as most important in making treatment decisions, specific functional outcomes as slightly less important, and duration, location, and cost of treatment as least important. Treatment choice was strongly impacted by side effect profile. Responses to whether the subject would agree to participation in a randomized trial between two types of radiation with minimal differences in outcomes were “yes” in 15%, “no” in 39%, and “undecided” in 46%. Responses to whether the subject would agree to participation in a randomized trial between two treatment durations with similar outcomes were yes in 36%, no in 24%, and undecided in 40%. Findings suggest many potential patients have strong treatment preferences and are averse to randomization, particularly when outcomes of importance may be affected. Patient engagement in study design and novel nonrandomized trial designs may offer a path to increase clinical trial success.
format	article
author	Nancy P. Mendenhall Sarah M. Rausch Osian Curtis M. Bryant Bradford S. Hoppe Christopher G. Morris
author_facet	Nancy P. Mendenhall Sarah M. Rausch Osian Curtis M. Bryant Bradford S. Hoppe Christopher G. Morris
author_sort	Nancy P. Mendenhall
title	What men want: Results from a national survey on decision making for prostate cancer treatment and research participation
title_short	What men want: Results from a national survey on decision making for prostate cancer treatment and research participation
title_full	What men want: Results from a national survey on decision making for prostate cancer treatment and research participation
title_fullStr	What men want: Results from a national survey on decision making for prostate cancer treatment and research participation
title_full_unstemmed	What men want: Results from a national survey on decision making for prostate cancer treatment and research participation
title_sort	what men want: results from a national survey on decision making for prostate cancer treatment and research participation
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/e601dda73bf44c2c8efdfb3f7a3a001a
work_keys_str_mv	AT nancypmendenhall whatmenwantresultsfromanationalsurveyondecisionmakingforprostatecancertreatmentandresearchparticipation AT sarahmrauschosian whatmenwantresultsfromanationalsurveyondecisionmakingforprostatecancertreatmentandresearchparticipation AT curtismbryant whatmenwantresultsfromanationalsurveyondecisionmakingforprostatecancertreatmentandresearchparticipation AT bradfordshoppe whatmenwantresultsfromanationalsurveyondecisionmakingforprostatecancertreatmentandresearchparticipation AT christophergmorris whatmenwantresultsfromanationalsurveyondecisionmakingforprostatecancertreatmentandresearchparticipation
_version_	1718420043763548160

What men want: Results from a national survey on decision making for prostate cancer treatment and research participation

Ejemplares similares